An observational study in Prostate Cancer, sponsored by Lantheus Medical Imaging. Active, not recruiting at 12 sites in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Lantheus Medical Imaging · Observational
The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan.
Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Biologically male patients with confirmed prostate cancer referred to undergo a PSMA PET with PYLARIFY.
Patients must meet all the following inclusion criteria:
Patients meeting the enrollment criteria for either Cohort 1 or Cohort 2:
Cohort 1:
Patients who are newly diagnosed with prostate cancer (and have suspected metastases per the physician's discretion per standard of care assessment) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET for identification of suspected metastases.
OR
Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not eligible for enrollment in this study:
Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET
Diagnostic Test: PYLARIFY
Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
Diagnostic Test: PYLARIFY
PYLARIFY PET
Primary Objective
The objective of this registry is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan and for whom PYLARIFY imaging is incorporated into treatment recommendations and management plans.
Time frame: 5 years
Secondary Objective 1
To understand the demographic and clinical characteristics of patients referred for PYLARIFY PET.
Time frame: 5 years
Secondary Objective 2
To understand the impact of PYLARIFY PET results on healthcare resource utilization.
Time frame: 5 years
Secondary Objective 3
To understand the role of PYLARIFY PET in treatment change management for newly diagnosed prostate cancer patients.
Time frame: 5 years
Secondary Objective 4
To understand the utilization of PYLARIFY PET at very low PSA levels in patients with oligometastatic prostate cancer.
Time frame: 5 years
Secondary Objective 5
To understand racial and ethnic disparities in prostate cancer care.
Time frame: 5 years
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lantheus Medical Imaging